Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/35616103http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/35616103http://www.w3.org/2000/01/rdf-schema#comment"

Context

Although the majority of RET alterations are single nucleotide variants (SNV), small deletions and/or insertions have been reported at variable prevalence. No information about the efficacy of RET-specific inhibitors in patients harboring RET indels has been provided.

Objective

We present an update on the prevalence of RET indels in medullary thyroid cancer (MTC) and describe the efficacy of selpercatinib in patients with advanced MTC with RET indels.

Methods

The MTC tissues of 287 patients were analyzed using an Ion S5 targeted sequencing. The functional role of the reported indels have been evaluated by MutationTaster. Clinical and pathological data of MTC patients harboring a RET indel were collected and analyzed. Two patients with a RET indel were treated with selpercatinib.

Results

Among 178 RET-positive cases, 147 (82.6%) harbored a SNV and 31 (17.4%) a RET in-frame indel. Nine indels were not previously reported and were found to be disease causing by MutationTaster. Patients harboring an indel were found to have an aggressive disease and 2 of them were treated with selpercatinib, experiencing a good response to the treatment.

Conclusion

These data show that RET indels are not infrequent and correlate with an aggressive disease. Two RET indel-positive patients showed a partial response to the treatment with a highly selective RET inhibitor; thus, these RET indels can be considered actionable mutations. In order to not miss these alterations, the analysis of the full gene is recommended."xsd:string
http://purl.uniprot.org/citations/35616103http://purl.org/dc/terms/identifier"doi:10.1210/clinem/dgac325"xsd:string
http://purl.uniprot.org/citations/35616103http://purl.uniprot.org/core/author"Matrone A."xsd:string
http://purl.uniprot.org/citations/35616103http://purl.uniprot.org/core/author"Elisei R."xsd:string
http://purl.uniprot.org/citations/35616103http://purl.uniprot.org/core/author"Ugolini C."xsd:string
http://purl.uniprot.org/citations/35616103http://purl.uniprot.org/core/author"Ciampi R."xsd:string
http://purl.uniprot.org/citations/35616103http://purl.uniprot.org/core/author"Prete A."xsd:string
http://purl.uniprot.org/citations/35616103http://purl.uniprot.org/core/author"Materazzi G."xsd:string
http://purl.uniprot.org/citations/35616103http://purl.uniprot.org/core/author"Romei C."xsd:string
http://purl.uniprot.org/citations/35616103http://purl.uniprot.org/core/author"Torregrossa L."xsd:string
http://purl.uniprot.org/citations/35616103http://purl.uniprot.org/core/author"Ramone T."xsd:string
http://purl.uniprot.org/citations/35616103http://purl.uniprot.org/core/author"Gambale C."xsd:string
http://purl.uniprot.org/citations/35616103http://purl.uniprot.org/core/author"Simeakis G."xsd:string
http://purl.uniprot.org/citations/35616103http://purl.uniprot.org/core/date"2022"xsd:gYear
http://purl.uniprot.org/citations/35616103http://purl.uniprot.org/core/name"J Clin Endocrinol Metab"xsd:string
http://purl.uniprot.org/citations/35616103http://purl.uniprot.org/core/pages"2195-2202"xsd:string
http://purl.uniprot.org/citations/35616103http://purl.uniprot.org/core/title"Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib."xsd:string
http://purl.uniprot.org/citations/35616103http://purl.uniprot.org/core/volume"107"xsd:string
http://purl.uniprot.org/citations/35616103http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/35616103
http://purl.uniprot.org/citations/35616103http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/35616103
http://purl.uniprot.org/uniprot/#_F5CNE9-mappedCitation-35616103http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35616103
http://purl.uniprot.org/uniprot/#_B4DGX8-mappedCitation-35616103http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35616103
http://purl.uniprot.org/uniprot/#_F8TLS5-mappedCitation-35616103http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35616103
http://purl.uniprot.org/uniprot/#_F8TLW0-mappedCitation-35616103http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/35616103
▶